Ready to Refer a Patient?
RadiantPath is now accepting referrals for mobile cancer care, including:
FDA-approved Pluvicto® (Lu-177 PSMA therapy) for eligible patients with PSMA-positive metastatic prostate cancer (mCRPC)
Diagnostic imaging, lab support, and medication delivery for a wide range of oncologic conditions
Customized services to meet the needs of rural, underserved, or immobile patients
We’ll handle the logistics — you stay focused on care.
Who Is Eligible for Pluvicto® Therapy?
Patients with:
• Confirmed diagnosis of metastatic castration-resistant prostate cancer (mCRPC)
• Positive PSMA PET/CT imaging
• Prior treatment with an AR pathway inhibitor (e.g., enzalutamide or abiraterone)
• No prior chemotherapy required (per March 2025 FDA update)
• Adequate organ and bone marrow function
How to Refer a Patient
Submit Referral
Send basic patient info and imaging results using our secure contact form via email, or EHR integration.
We Coordinate Everything
Our team confirms eligibility, handles authorizations, and prepares the patient for on-site therapy at your clinic.
Treat
Our team coordinates onsite Lu-177 therapy, delivering infusions every six weeks with clinical oversight.
Receive Documentation
We provide complete treatment notes, follow-up plans, and coding support to ensure continuity of care.
Flexible Service Models
Tailored to Fit Your Practice Needs
At RadiantPath, we offer two distinct models to support your oncology program — whether you’re looking to refer patients or integrate theranostics directly into your care delivery.
Option 1: RadiantPath as the Referral Provider
We handle the drug, staffing, and infrastructure.
Your team refers the patient, and we manage the entire treatment process — from therapy delivery to clinical oversight.
Option 2: RadiantPath as the Service Vendor
You retain the patient relationship.
Your practice purchases the radioligand medication, bills for the therapy, and leads clinical coordination — while we provide the mobile infrastructure, onsite support, and delivery platform.
Our scalable models are ideal for practices experiencing patient leakage, geographic barriers, or limitations in in-house resources.
RadiantPath ensures every patient gets access to cutting-edge theranostics — wherever they are.
Let's Expand Access Together
Have a patient in mind?
We’ll walk with you through every step of the referral and treatment process — from eligibility to documentation.
Let’s bring targeted cancer care where it’s needed most.